K. McDougall

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

J. Fletcher, G. Demetri, H. Joensuu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).

E. Jaffee, K. McDougall, Z. Wainberg, 2017 .

Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma

E. Jaffee, L. Coussens, K. McDougall, 2019, Clinical Cancer Research.

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.

J. Burke, J. Radich, H. Kantarjian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR).

E. Jaffee, T. Crocenzi, K. McDougall, 2016 .

Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR)

E. Jaffee, T. Crocenzi, K. McDougall, 2015, Journal of Immunotherapy for Cancer.

Antimesothelin vaccine CRS-207 plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM).

K. McDougall, H. Kindler, S. Antonia, 2014 .

Pulse dose imatinib (Im) and weekly paclitaxel (P) phase I trial for advanced refractory solid tumors

J. Marshall, K. McDougall, M. Egorin, 2005 .

Molecular Responses in Newly Diagnosed Chronic Myelocytic Leukemia (CML) Patients Treated with 800 mg Imatinib Daily: An Update from the RIGHT Trial Study Group.

J. Radich, H. Kantarjian, K. McDougall, 2006 .

Mesothelin-targeted immunotherapy CRS-207 in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM).

K. McDougall, H. Kindler, S. Antonia, 2015 .